Publicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (5)

2016

  1. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

    European Journal of Cancer, Vol. 56, pp. 85-92

2015

  1. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

    European Journal of Cancer

  2. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results of NCIC CTG MA.31

    Journal of Clinical Oncology, Vol. 33, Núm. 14, pp. 1574-1583

  3. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

    Breast Cancer Research, Vol. 17, Núm. 1

2013

  1. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: A randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 14, Núm. 1, pp. 88-96